Forte Biosciences Inc FBRX
76.99 USD 0.00 (+0.00%)
At closeAug 26, 2026, 4:00 PM EDT
21.03 -55.96 -72.68%
After hours · Aug 26, 4:00 PM ET
76.96 Day range 77.00
10.11 52-week range 77.20
- YTD
- +182.32%
- 1 year
- +574.76%
Analyst view
Consensus: buy
Buy
Price target (mean) 73.00 -5.2% downside
Now 76.99
- Target (low)
- 61.00
- Target (mean)
- 73.00
- Target (high)
- 77.00
Ratings (0m) 4 1 buy · 3 hold · 0 sell
- Strong buy0
- Buy1
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 5
- 2 months ago 5
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.09 | -1.09 – -1.09 | -0.99 | -10.1% | 0 | 0.0% | 1 |
| Next quarter | -1.11 | -1.11 – -1.11 | -1.45 | +23.4% | 0 | 0.0% | 1 |
| Current year | -4.48 | -4.48 – -4.48 | -4.71 | +4.9% | 0 | 0.0% | 1 |
| Next year | -4.08 | -5.91 – -2.89 | -4.48 | +9.0% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 28, 2026 | Barclays | Downgrade | Overweight | Equal-Weight |
| Jul 21, 2026 | Barclays | Initiated | — | Overweight |
| Nov 25, 2025 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 17, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Aug 18, 2025 | Guggenheim | Initiated | — | Buy |
| Aug 15, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Jun 24, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Apr 1, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Jan 21, 2025 | TD Cowen | Initiated | — | Buy |
| Dec 4, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 15, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Aug 19, 2024 | Chardan Capital | Maintained | Buy | Buy |
| May 30, 2024 | Brookline Capital | Initiated | — | Buy |
| Apr 8, 2024 | Ladenburg Thalmann | Upgrade | Neutral | Buy |
| Sep 20, 2021 | Chardan Capital | Upgrade | Sell | Neutral |
| Sep 3, 2021 | Brookline Capital | Downgrade | Buy | Hold |
| Sep 3, 2021 | Chardan Capital | Downgrade | Buy | Sell |
| Sep 3, 2021 | Ladenburg Thalmann | Downgrade | Buy | Neutral |
| Sep 3, 2021 | B. Riley Securities | Downgrade | Buy | Neutral |
| Sep 3, 2021 | Truist Securities | Downgrade | Buy | Hold |
| May 14, 2021 | B. Riley Securities | Initiated | — | Buy |
| Mar 26, 2021 | Citigroup | Initiated | — | Buy |
| Mar 17, 2021 | Chardan Capital | Maintained | — | Buy |
| Sep 24, 2020 | Chardan Capital | Maintained | — | Buy |
| Sep 10, 2020 | Chardan Capital | Maintained | — | Buy |
| Aug 28, 2020 | Brookline Capital | Initiated | — | Buy |
| Aug 28, 2020 | Chardan Capital | Upgrade | Neutral | Buy |
| Aug 25, 2020 | Truist Securities | Initiated | — | Buy |
| Jun 22, 2020 | Ladenburg Thalmann | Initiated | — | Buy |